File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.schres.2006.01.011
- Scopus: eid_2-s2.0-33646469840
- PMID: 16524698
- WOS: WOS:000237012200010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia
Title | Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia |
---|---|
Authors | |
Keywords | Clozapine Norclozapine Relapse Schizophrenia Serum concentration |
Issue Date | 2006 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schres |
Citation | Schizophrenia Research, 2006, v. 83 n. 2-3, p. 201-210 How to Cite? |
Abstract | Schizophrenic outpatients (n = 102) whose condition had stabilized with clozapine (CLZ) therapy and were being maintained on CLZ were followed for 1 year. Clinical status and concentrations of serum clozapine (CLZ) and its metabolite norclozapine (NCLZ) were evaluated periodically or when relapse occurred. Relapse was defined as a significant exacerbation of psychotic symptoms or hospitalization. Thirty-three patients relapsed and 69 did not. Relapse patients displayed significantly lower serum concentrations of CLZ and a sum of CLZ and NCLZ at endpoint than non-relapses (CLZ: 162 ng/ml vs. 237 ng/ml, p < 0.001; CLZ + NCLZ: 225 ng/ml vs. 301 ng/ml, p < 0.001). When all subjects were pooled together, a significant inverse correlation was observed between percent increase in the total score on the Brief Psychiatric Rating Scale (BPRS) from baseline and serum levels of CLZ alone (r = 0.404, p < 0.001) and the sum of CLZ and NCLZ (r = 0.364, p < 0.001). Relapses and non-relapses were well separated by a threshold CLZ serum concentration of 200 ng/ml with a sensitivity of 73% and a specificity of 80%. The threshold value represented about a 40% lower serum CLZ level than concentration achieved in acute treatment. Survival analysis showed a similarity of the relapse risk over time defined by the CLZ serum threshold and by symptomatic criteria. These results suggest that effective relapse prevention may require maintenance of patients at CLZ serum concentrations above 200 ng/ml and above 60% of the acute-phase level during long-term maintenance treatment of schizophrenia. © 2006 Elsevier B.V. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/179434 |
ISSN | 2023 Impact Factor: 3.6 2023 SCImago Journal Rankings: 1.374 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Xiang, YQ | en_US |
dc.contributor.author | Zhang, ZJ | en_US |
dc.contributor.author | Weng, YZ | en_US |
dc.contributor.author | Zhai, YM | en_US |
dc.contributor.author | Li, WB | en_US |
dc.contributor.author | Cai, ZJ | en_US |
dc.contributor.author | Tan, QR | en_US |
dc.contributor.author | Wang, CY | en_US |
dc.date.accessioned | 2012-12-19T09:56:28Z | - |
dc.date.available | 2012-12-19T09:56:28Z | - |
dc.date.issued | 2006 | en_US |
dc.identifier.citation | Schizophrenia Research, 2006, v. 83 n. 2-3, p. 201-210 | en_US |
dc.identifier.issn | 0920-9964 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/179434 | - |
dc.description.abstract | Schizophrenic outpatients (n = 102) whose condition had stabilized with clozapine (CLZ) therapy and were being maintained on CLZ were followed for 1 year. Clinical status and concentrations of serum clozapine (CLZ) and its metabolite norclozapine (NCLZ) were evaluated periodically or when relapse occurred. Relapse was defined as a significant exacerbation of psychotic symptoms or hospitalization. Thirty-three patients relapsed and 69 did not. Relapse patients displayed significantly lower serum concentrations of CLZ and a sum of CLZ and NCLZ at endpoint than non-relapses (CLZ: 162 ng/ml vs. 237 ng/ml, p < 0.001; CLZ + NCLZ: 225 ng/ml vs. 301 ng/ml, p < 0.001). When all subjects were pooled together, a significant inverse correlation was observed between percent increase in the total score on the Brief Psychiatric Rating Scale (BPRS) from baseline and serum levels of CLZ alone (r = 0.404, p < 0.001) and the sum of CLZ and NCLZ (r = 0.364, p < 0.001). Relapses and non-relapses were well separated by a threshold CLZ serum concentration of 200 ng/ml with a sensitivity of 73% and a specificity of 80%. The threshold value represented about a 40% lower serum CLZ level than concentration achieved in acute treatment. Survival analysis showed a similarity of the relapse risk over time defined by the CLZ serum threshold and by symptomatic criteria. These results suggest that effective relapse prevention may require maintenance of patients at CLZ serum concentrations above 200 ng/ml and above 60% of the acute-phase level during long-term maintenance treatment of schizophrenia. © 2006 Elsevier B.V. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schres | en_US |
dc.relation.ispartof | Schizophrenia Research | en_US |
dc.subject | Clozapine | - |
dc.subject | Norclozapine | - |
dc.subject | Relapse | - |
dc.subject | Schizophrenia | - |
dc.subject | Serum concentration | - |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Analysis Of Variance | en_US |
dc.subject.mesh | Antipsychotic Agents - Blood - Therapeutic Use | en_US |
dc.subject.mesh | Brief Psychiatric Rating Scale | en_US |
dc.subject.mesh | Clozapine - Analogs & Derivatives - Blood - Therapeutic Use | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Follow-Up Studies | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Predictive Value Of Tests | en_US |
dc.subject.mesh | Prospective Studies | en_US |
dc.subject.mesh | Recurrence | en_US |
dc.subject.mesh | Schizophrenia - Blood - Drug Therapy | en_US |
dc.subject.mesh | Statistics As Topic | en_US |
dc.subject.mesh | Time Factors | en_US |
dc.title | Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia | en_US |
dc.type | Article | en_US |
dc.identifier.email | Zhang, ZJ: zhangzj@hkucc.hku.hk | en_US |
dc.identifier.authority | Zhang, ZJ=rp01297 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.schres.2006.01.011 | en_US |
dc.identifier.pmid | 16524698 | - |
dc.identifier.scopus | eid_2-s2.0-33646469840 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-33646469840&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 83 | en_US |
dc.identifier.issue | 2-3 | en_US |
dc.identifier.spage | 201 | en_US |
dc.identifier.epage | 210 | en_US |
dc.identifier.isi | WOS:000237012200010 | - |
dc.publisher.place | Netherlands | en_US |
dc.identifier.scopusauthorid | Xiang, YQ=35742320200 | en_US |
dc.identifier.scopusauthorid | Zhang, ZJ=8061473900 | en_US |
dc.identifier.scopusauthorid | Weng, YZ=7103320159 | en_US |
dc.identifier.scopusauthorid | Zhai, YM=7102983468 | en_US |
dc.identifier.scopusauthorid | Li, WB=36066834700 | en_US |
dc.identifier.scopusauthorid | Cai, ZJ=7402902177 | en_US |
dc.identifier.scopusauthorid | Tan, QR=7102120177 | en_US |
dc.identifier.scopusauthorid | Wang, CY=35345843000 | en_US |
dc.identifier.issnl | 0920-9964 | - |